

《大腸直腸癌抗癌藥物治療指引》

Adjuvant Therapy of Colon Cancer

mFOLFOX6

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	12	1-3
Leucovorin	400	1	Q2W	12	1-3
5-FU	400	1	Q2W	12	1-3
5-FU	1200*	1-2	Q2W	12	1-3

* Continuous infusion for 24 hours

FOLFOX4

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	12	8
Leucovorin	200	1	Q2W	12	8
5-FU	400	1	Q2W	12	8
5-FU	600*	1-2	Q2W	12	8

* Continuous infusion for 24 hours

FOLFOX7

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W		11
Leucovorin	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

Capecitabine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1250 PO BID	1-14	Q3W	8	4

CapeOx

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	1	Q3W	8	5
Capecitabine	1000 PO BID	1-14	Q3W	8	5

5-FU+LV

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Leucovorin	500	1, 8, 15, 22, 29, 36	Q8W	4	6
5-FU	500	1, 8, 15, 22, 29, 36	Q8W	4	6

sLV5FU2

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Leucovorin	400	1	Q2W	12	7
5-FU	400	1	Q2W	12	7
5-FU	1200*	1-2	Q2W	12	7

* Continuous infusion for 24 hours

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
UFUR	300-350/day PO	1-28	Q4W	6	9
± Leucovorin	50-150 mg PO QD	1-28	Q4W	6	

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
TS-1	40 PO BID	1-28	Q6W	4	10

Neoadjuvant Therapy of Colon Cancer

同 1st line therapy of metastatic colon cancer

參考文獻

1. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med* 2004;350:2343-2351.
2. Cheeseman SL, Joel SP, Chester JD, et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. *Br J Cancer* 2002;87:393-399.
3. Maindrault-Goebel F, deGramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. *Annals of Oncology* 2000;11:1477-1483.
4. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. *N Engl J Med* 2005;352:2696-2704.
5. Schmoll HJ, Cartwright T, Taerner J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. *J Clin Oncol* 2007;25:102-109.
6. Haller DG, Catalano P, Macdonald JS, Mayer RJ. Phase III study of fluorouracil, leucovorin and levamisole in high risk stage II and III colon cancer: final report of Intergroup 0089. *J Clin Oncol* 2005;23:8671-8678.
7. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. *Eur J Cancer* 1999;35(9):1343-7.

8. deGramont A, Figer A, Seymour M, et al. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. *J Clin Oncol* 2000;18:2938-2947.
9. Sulkes A, Benner SE, Canetta RM. Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. *J Clin Oncol*. Oct 1998;16(10):3461-3475.
10. Hamaguchi, Tetsuya et al. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. *The Lancet Gastroenterology & Hepatology*, Volume 3, Issue 1, 47 – 56.
11. Tezuka T, Hamada C, Ishida H, et al. Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study. *Invest New Drugs*. 2013 Oct;31(5):1321-9.

Adjuvant Therapy of Rectal Cancer

Chemotherapy

mFOLFOX6

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	12	1-3
Leucovorin	400	1	Q2W	12	
5-FU	400	1	Q2W	12	
5-FU	1200*	1-2	Q2W	12	

* Continuous infusion for 24 hours

sLV5FU2

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Leucovorin	400	1	Q2W	12	4, 13
5-FU	400	1	Q2W	12	
5-FU	1200*	1-2	Q2W	12	

* Continuous infusion for 24 hours

Capecitabine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1250 PO BID	1-14	Q3W	8	5

CapeOx

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	1	Q3W	8	6, 7
Capecitabine	1000 PO BID	1-14	Q3W	8	

5-FU+LV

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Leucovorin	500	1, 8, 15, 22, 29, 36	Q8W	4	8
5-FU	500	1, 8, 15, 22, 29, 36	Q8W	4	

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
UFUR	300-350/day PO	1-28	Q4W	6	14
± Leucovorin	50-150 mg PO QD	1-28	Q4W	6	

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
TS-1	40 PO BID	1-28	Q42D	4	15

Chemotherapy + RT

XRT + continuous infusion 5-FU

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
5-FU	225	1-5 or 1-7	Q4W	During XRT	9

XRT + 5-FU/LV

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
5-FU	400	1-4	Q4W	During week 1, 5 of XRT	10
Leucovorin	20	1-4	Q4W		

XRT + Capecitabine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	825 PO BID	1-5	QW	5	11, 12

XRT + mFOLFOX6

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1			16
Leucovorin	400	1			
5-FU	400	1			
5-FU	1200*	1-2			

* Continuous infusion for 24 hours

Neoadjuvant Therapy of Rectal Cancer
FOLFOX

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	6	16
Leucovorin	400	1	Q2W	6	
5-FU	400	1	Q2W	6	
5-FU	1200*	1-2	Q2W	6	

* Continuous infusion for 24 hours

CapeOx

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	1	Q3W	4	17
Capecitabine	1000 PO BID	1-14	Q3W	4	

FOLFIRINOX (T4, N+)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	12	20
Leucovorin	400	1	Q2W	12	
Irinotecan	180	1	Q2W	12	
5-FU	400	1	Q2W	12	
5-FU	1200*	1-2	Q2W	12	

* Continuous infusion for 24 hours

mFOLFIRINOX (T4, N+)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	12	21
Leucovorin	400	1	Q2W	12	
Irinotecan	150	1	Q2W	12	
5-FU	1200*	1-2	Q2W	12	

* Continuous infusion for 24 hours

Therapy after CCRT

UFUR + LV

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
UFUR	250 mg/m ² PO QD		QW		18, 19
Folina	45 mg PO QD		QW		

參考文獻

1. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med* 2004;350:2343-2351.
2. Cheeseman SL, Joel SP, Chester JD, et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. *Br J Cancer* 2002;87:393-399.
3. Maindrault-Goebel F, deGramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. *Annals of Oncology* 2000;11:1477-1483.
4. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. *Eur J Cancer* 1999;35(9):1343-7.
5. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. *N Engl J Med* 2005;352:2696-2704.
6. Schmoll HJ, Cartwright T, Taernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. *J Clin Oncol* 2007;25:102-109.
7. Haller DG, Tabernero J, Maroun J, et al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer. *J Clin Oncol* 2011;29:1465-1471.

8. Petrelli N, Douglass Jr HO, Herrare L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: 40 a prospective randomized phase III trial. *J Clin Oncol* 1989;7:1419-1426.
9. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. *N Engl J Med* 1994;331:502-507.
10. Tepper JE, O'Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of Intergroup 0114. *J Clin Oncol* 2002;20:1744-1750.
11. O'Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. *J Clin Oncol* 2014;32:1927-1934.
12. Hofheinz R, Wenz FK, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomized, multicenter, non-inferiority, phase 3 trial. *Lancet Oncol* 2012;13:579-588.
13. Shikina A, Shinto E, Hashiguchi Y, et al. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status. *Jpn J Clin Oncol*. Jan 2014;44(1):42-48.
14. Sulkes A, Benner SE, Canetta RM. Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. *J Clin Oncol*. Oct 1998;16(10):3461-3475.
15. Hamaguchi, Tetsuya et al. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. *The Lancet Gastroenterology & Hepatology*, Volume 3, Issue 1, 47 – 56.
16. Koizumi M, Yamada T, Shinji S, et al. Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer. *In Vivo*. 2018; 32(4): 937–943.
17. Hata T, Takahashi H, Sakai D, et al. Neoadjuvant CapeOx therapy followed by sphincter-preserving surgery for lower rectal cancer. *Surg Today* (2017) 47: 1372.
18. Wang LW, Yang SH, Lin JK, et al. Pre-operative chemoradiotherapy with oral tegafur-uracil and leucovorin for rectal cancer. *J Surg Oncol*. 2005 Mar 15;89(4):256-63; discussion 263-4. doi: 10.1002/jso.20168. Erratum in: *J Surg Oncol*. 2005 May 1;90(2):106. PMID: 15726610.
19. Fokas E, Schlenska-Lange A, Polat B, et al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total

- Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. *JAMA Oncol.* Published online November 18, 2021. doi:10.1001/jamaoncol.2021.5445
20. Conroy T, Bosset JF, Etienne PL, et al.,. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. *The Lancet Oncology* 2021;22;702-715.
 21. Bennouna J, André T, Campion L, et al., Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial. *Clin Colorectal Cancer.* 2019 Mar;18(1):e69-e73.

Chemotherapy for Advanced or Metastatic Colon and Rectal Cancer

First-line therapy

mFOLFOX6 or mFOLFOX7

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	8-12	1, 2, 3, 28
Leucovorin	400	1	Q2W	8-12	
5-FU (optional)	400	1	Q2W	8-12	
5-FU	1200*	1-2	Q2W	8-12	

* Continuous infusion for 24 hours

FOLFOX + Bevacizumab

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Bevacizumab	5 mg/kg	1	Q2W		4
Oxaliplatin	85	1	Q2W		
Leucovorin	400	1	Q2W		
5-FU (optional)	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

FOLFOX + Panitumumab (KRAS/NRAS WT gene only)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Panitumumab	6 mg/kg	1	Q2W		5
Oxaliplatin	85	1	Q2W		
Leucovorin	400	1	Q2W		
5-FU (optional)	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

FOLFOX + Cetuximab (KRAS/NRAS WT gene only)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cetuximab	500 (400 → 250)	1	Q2W (QW)		6
Oxaliplatin	85	1	Q2W		
Leucovorin	400	1	Q2W		
5-FU (optional)	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

Xelox

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q2W	Max 12	33
Capecitabine	1000 PO BID	1-7	Q2W	Max 12	

CapeOx

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	1	Q3W	Max 16	7
Capecitabine	1000 PO BID	1-14	Q3W	Max 16	

CapeOx + Bevacizumab

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Bevacizumab	7.5 mg/kg	1	Q3W	Max 16	7
Oxaliplatin	130	1	Q3W	Max 16	
Capecitabine	1000 PO BID	1-14	Q3W	Max 16	

FOLFIRI

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Irinotecan	180	1	Q2W		8, 9
Leucovorin	400	1	Q2W		
5-FU (optional)	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

FOLFIRI + Bevacizumab

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Bevacizumab	5 mg/kg	1	Q2W		10
Irinotecan	180	1	Q2W		
Leucovorin	400	1	Q2W		
5-FU (optional)	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

FOLFIRI + Cetuximab (KRAS/NRAS WT gene only)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cetuximab	500 (400 → 250)	1	Q2W (QW)		11, 12
Irinotecan	180	1	Q2W		
Leucovorin	400	1	Q2W		
5-FU (optional)	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

FOLFIRI + Panitumumab (KRAS/NRAS WT gene only)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Panitumumab	6 mg/kg	1	Q2W		13
Irinotecan	180	1	Q2W		
Leucovorin	400	1	Q2W		
5-FU (optional)	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

Capecitabine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1000 (825-1250) PO BID	1-14	Q3W		16

Capecitabine + Bevacizumab

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Bevacizumab	7.5 mg/kg	1	Q3W		16
Capecitabine	1000 (825-1250) PO BID	1-14	Q3W		

(m)FOLFIRINOX ± Bevacizumab

藥品名	劑量 * mg/m ²	給藥日	頻率	週期	參考文獻
± Bevacizumab	5 mg/kg	1	Q2W		21, 22, 43
Oxaliplatin	85	1	Q2W		
Irinotecan	150(m) or 180	1	Q2W		
Leucovorin	400	1	Q2W		
5-Fu (optional)	400	1	Q2W		
5-Fu	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

(m)FOLFIRINOX ± Cetuximab

藥品名	劑量 * mg/m ²	給藥日	頻率	週期	參考文獻
± Cetuximab	500 (400 → 250)	1	Q2W/QW		21, 40, 43
Oxaliplatin	85	1	Q2W		
Irinotecan	150(m) or 180	1	Q2W		
Leucovorin	400	1	Q2W		
5-Fu (optional)	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

(m)FOLFIRINOX ± Panitumumab

藥品名	劑量 * mg/m ²	給藥日	頻率	週期	參考文獻
± Panitumumab	6 mg/kg	1	Q2W/QW		21, 40, 43
Oxaliplatin	85	1	Q2W		
Irinotecan	150(m) or 180	1	Q2W		
Leucovorin	400	1	Q2W		
5-Fu (optional)	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

Cetuximab (KRAS/NRAS WT gene only)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cetuximab	500 (400 → 250)	1	Q2W (QW)		12, 25

Panitumumab (KRAS/NRAS WT gene only)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Panitumumab	6 mg/kg	1	Q2W		26

Pembrolizumab (MSI-H)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Pembrolizumab	2 mg/kg	1	Q3W		29

Nivolumab (MSI-H)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	1	Q2W		30

Nivolumab (MSI-H)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	1	Q2W		30

Nivolumab + Ipilimumab (MSI-H)

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	1	Q3W	4	36
Ipilimumab	1 mg/kg	1	Q3W		
Followed by					
Nivolumab	3 mg/kg or 240 mg	1	Q2W		

Bolus or Infusional 5FU/Leucovorin

Roswell Park

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Leucovorin	500	1, 8, 15, 22, 29, 36	Q8W		17
5-FU	500	1, 8, 15, 22, 29, 36	Q8W		

Simplified biweekly infusional 5-FU/LV (sLV5FU2)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Leucovorin	400	1	Q2W		8
5-FU	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

Infusional 5-FU/LV (sLV5FU2) + Bevacizumab

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Bevacizumab	5 mg/kg	1	Q2W		39
Leucovorin	400	1	Q2W		
5-FU	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

Weekly

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Leucovorin	20	1	QW		18
5-FU	500	1	QW		

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Leucovorin	500	1	QW		19
5-FU	2600	1	QW		

Second-line and other therapy ★

FOLFIRI + Ziv-aflibercept

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Ziv-aflibercept	4 mg/kg	1	Q2W		14
Irinotecan	180	1	Q2W		
Leucovorin	400	1	Q2W		
5-FU (optional)	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

FOLFIRI + Ramucirumab

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Ramucirumab	8 mg/kg	1	Q2W		15
Irinotecan	180	1	Q2W		
Leucovorin	400	1	Q2W		
5-FU (optional)	400	1	Q2W		
5-FU	1200*	1-2	Q2W		

* Continuous infusion for 24 hours

IROX

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	1	Q3W		20
Irinotecan	200	1	Q3W		

Irinotecan

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Irinotecan	125 (180) (300-350)	1, 8 (1)	Q3W (Q2W)(Q3W)		23, 24

Cetuximab + Irinotecan (KRAS/NRAS WT gene only)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cetuximab	500 (400 → 250)	1	Q2W (QW)		12, 25
Irinotecan	125 (180) (300-350)	1, 8 (1)	Q3W (Q2W)(Q3W)		

Irinotecan + Panitumumab (KRAS/NRAS/BRAF WT only)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Panitumumab	6 mg/kg	1	Q2W		13
Irinotecan	125 (180) (300-350)	1, 8 (1)	Q3W (Q2W)(Q3W)		

Irinotecan + Ramucirumab

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Ramucirumab	8 mg/kg	1	Q2W		15
Irinotecan	125 (180) (300-350)	1, 8 (1)	Q3W (Q2W)(Q3W)		

Regorafenib

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Regorafenib	160 mg PO	1-21	Q4W		27

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Regorafenib	80 → 120 → 160 mg PO	1-7 → 8-14 → 15-21	Q4W	1	35
Followed by Regorafenib	160 mg PO	1-21	Q4W		

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
UFUR	200mg PO BID/TID	1-28	Q4W		31

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
TS-1	50-75mg PO BID	1-28	Q42D		32

Trastuzumab + Pertuzumab (HER2-amplified and RAS WT)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Trastuzumab	8 → 6 mg/kg	1	Q3W		37
Pertuzumab	840 → 420 mg	1	Q3W		

Dabrafenib + Trametinib + Cetuximab (BRAF V600E mutation+)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Dabrafenib	150 mg PO BID	1-7	QW		38
Trametinib	2 mg PO QD	1-7	QW		
Cetuximab	400 → 250	1	QW		

Dabrafenib + Trametinib + Panitumumab (BRAF V600E mutation+)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Dabrafenib	150 mg PO BID	1-14	Q2W		38
Trametinib	2 mg PO QD	1-14	Q2W		
Panitumumab	6 mg/kg	1	Q2W		

Encorafenib + Cetuximab (BRAF V600E mutation+)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cetuximab	400 → 250	1	QW		41
Encorafenib	300 mg PO QD				

Encorafenib + Panitumumab (BRAF V600E mutation+)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Panitumumab	6 mg/kg	1	Q2W		41
Encorafenib	300 mg PO QD				

Dabrafenib + Trametinib + Cetuximab (BRAF V600E mutation+)

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cetuximab	400 → 250	1	QW		42
Dabrafenib	150 mg PO BID	1-7	QW		
Trametinib	2 mg PO QD	1-7	QW		

Dabrafenib + Trametinib + Panitumumab (BRAF V600E mutation+)

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Panitumumab	6 mg/kg	1	Q2W		42
Dabrafenib	150 mg PO BID	1-14	Q2W		
Trametinib	2 mg PO QD	1-14	Q2W		

Larotrectinib (NTRK fusion+)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Larotrectinib	100 mg PO BID				44

Larotrectinib (NTRK fusion+)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Entrectinib	600 mg PO QD				45

*三院有個別版本

參考文獻

1. deGramont A, Figer A, Seymour M, et al. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. J Clin Oncol 2000;18:2938-2947.
2. Cheeseman SL, Joel SP, Chester JD, et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002;87:393-399.

3. Maindrault-Goebel F, deGramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. *Ann Oncol* 2000;11:1477-1483.
4. Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. *BMC Cancer* 2007;7:91.
5. Douillard JY, Siena S, Cassidy J, et al. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. *J Clin Oncol* 2010;28:4697-4705.
6. Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum [abstract]. *ASCO Meeting Abstracts* 2014;32:LBA3.
7. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. *J Clin Oncol* 2008;26:2013-2019.
8. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. *Eur J Cancer* 1999;35(9):1343-7.
9. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study. *J Clin Oncol* 2007;25:4779-4786.
10. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2014.
11. Cunningham D, Humblet Y, Siena S, et al. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. *N Engl J Med* 2004;351:337-345.
12. Martin-Martorell P, Rosello' S, Rodriguez-Braun E, et al. Biweekly cetuximab and irinotecan in advanced colorectal cancer 50 patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. *Br J Cancer*

- 2008;99:455-458.
13. Peeters M, Prince TJ, Cervantes A, et al. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. *J Clin Oncol* 2010;28:4706-4713.
 14. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. *J Clin Oncol* 2012;30:3499-3506.
 15. Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomized, double-blind, multicentre, phase 3 study. *Lancet Oncol* 2015;16:499-508.
 16. Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. *Lancet Oncol* 2013;14:1077-1085.
 17. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. *J Clin Oncol* 1993;11:1879-1887.
 18. Jäger E, Heike M, Bemhard H, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. *J Clin Oncol* 1996;14:2274-2279.
 19. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *The Lancet* 2000;355:1041-47.
 20. Haller DG, Rothenberg ML, Wong AO, et al. Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma. *J Clin Oncol* 2008;26:4544-4550.
 21. Falcone A, Ricci S, Brunetti I, et al. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. *J Clin Oncol* 2007;25(13):1670-1676.

22. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. *Lancet Oncol* 2015;16:1306-1315.
23. Cunningham D, Pyrhonen S, James R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. *The Lancet* 1998;352:1413-1418.
24. Fuchs CS, Moore MR, Harker G, et al. Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal Cancer. *J Clin Oncol* 2003;21:807-814.
25. Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Inpatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. *J Clin Oncol* 2012;30:2861-2868.
26. Van Cutsem E, Peeters M, Siena S, et al. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. *J Clin Oncol* 2007;25:1658-1664.
27. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381:303-312.
28. Hochster HS, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. *Ann Oncol* 2014;25:1172-1178.
29. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med*. Jun 25 2015;372(26):2509-2520.
30. Overman MJ, McDermott RS, et al. Nivolumab {+/-} ipilimumab in treatment of patients with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results [abstract]. *ASCO Meeting Abstracts* 2016;34:3501. 2016.
31. Product Information: UFUR Capsule. tegafur, uracil oral capsules. 2015.
32. Product Information: TS-1 capsules. Tegafur, Gimeracil, Oteracil potassium oral capsules. 2015.
33. Overman MJ, Lonardi S, Wong K, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-

- Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer. *J Clin Oncol* 2018;36:773-779.
34. Grande C, Quintero G, Candamio S, et al. Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer. *Journal of Geriatric Oncology* 2013;4: 114-121.
 35. Bekaii-Saab TS, Ou F-S, Anderson DM, et al. Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)-An ACCRU Network study. *J Clin Oncol* 2018;36(suppl 4S;abstr 611).
 36. Grande C, Quintero G, Candamio S, et al. Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer. *Journal of Geriatric Oncology* 2013;4: 114-121.
 37. Meric-Bernstam F, Hurwitz H, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. *Lancet Oncol.* 2019;20(4):518-530.
 38. Atreya CE, Van Cutsem E, et al. Phase 1/2 study of the MEK inhibitor trametinib, BRAF inhibitor Dabrafenib, and anti-EGFR antibody Panitumumab in patients with BRAF V600E-mutated metastatic colorectal cancer. *J Clin Oncol* 2015;33(suppl; abstr 103).
 39. Nakayama N, Sato A, Tanaka S, Shimada K, et al. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study. *Invest New Drugs.* 2015 Aug;33(4):954-62.
 40. Cremolini C, Antoniotti C, Lonardi S, et al. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. *JAMA Oncol.* 2018 Apr 1;4(4):529-536. doi: 10.1001/jamaoncol.2017.5314. PMID: 29450468; PMCID: PMC5885260.
 41. Scott Kopetz, Axel Grothey, Eric Van Cutsem, Rona Yaeger, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). *Journal of Clinical Oncology* 2020 38:4_suppl, 8-8.
 42. Atreya CE, Van Cutsem E, et al. Phase 1/2 study of the MEK inhibitor trametinib, BRAF inhibitor Dabrafenib, and anti-EGFR antibody Panitumumab in patients with BRAF V600E-mutated metastatic colorectal cancer. *J Clin Oncol* 2015;33(suppl; abstr 103).

43. Bennouna J, André T, Campion L, et al., Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial. *Clin Colorectal Cancer*. 2019 Mar;18(1):e69-e73.
44. Drilon A, Laetsch TW, Kummar S, et al., Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N Engl J Med*. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.
45. Doebele RC, Drilon A, Paz-Ares L, et al., Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol*. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Erratum in: *Lancet Oncol*. 2020 Feb;21(2):e70. Erratum in: *Lancet Oncol*. 2020 Jul;21(7):e341. Erratum in: *Lancet Oncol*. 2020 Aug;21(8):e372. Erratum in: *Lancet Oncol*. 2021 Oct;22(10):e428.